Publicacións nas que colabora con Francisco Javier González Barcala (21)

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort

    Journal of investigational allergology & clinical immunology, Vol. 34, Núm. 3, pp. 192-195

  3. The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria

    Respiratory Medicine, Vol. 226

2023

  1. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 11, pp. 3407-3413.e1

  2. Does asthma-bronchiectasis overlap syndrome (ABOS) really exist?

    Journal of Asthma, Vol. 60, Núm. 11, pp. 1935-1941

  3. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  4. Identification of Asthma Phenotypes in the Spanish MEGA Cohort Study Using Cluster Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 223-231

  5. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti–IL-5 Biologics: A Real-Life Study

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 1, pp. 37-44

  6. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 294-296

  7. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps

    Clinical Reviews in Allergy and Immunology, Vol. 64, Núm. 2, pp. 179-192

  8. Reply to “Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies”

    Journal of Investigational Allergology and Clinical Immunology

  9. Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 1, pp. 141-155

  10. The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 608-611

2022

  1. Anxiety and body mass index affect asthma control: data from a prospective Spanish cohort

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 3, pp. 863-866.e1

  2. How reliably can algorithms identify eosinophilic asthma phenotypes using non-invasive biomarkers?

    Clinical and Translational Allergy, Vol. 12, Núm. 8

  3. The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids

    ERJ Open Research

  4. With the Torch in the Mist of the United Airway Disease: Atopic March and Other Arguments in the Search for Evidence

    Archivos de Bronconeumologia

  5. [Translated article] With the Torch in the Mist of the United Airway Disease: Atopic March and Other Arguments in the Search for Evidence

    Archivos de Bronconeumologia

2018

  1. Expansion of a CD26low effector th subset and reduction in circulating levels of sCD26 in stable allergic asthma in adults

    Journal of Investigational Allergology and Clinical Immunology, Vol. 28, Núm. 2, pp. 113-125

2017

  1. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma

    BMJ Open Respiratory Research, Vol. 4, Núm. 1